Sequestration Kicks In: FDA Will Manage For Now, But Could Suffer Aftereffects
This article was originally published in The Rose Sheet
Executive Summary
With the implementation of across-the-board spending cuts, FDA will be unable to add the hundreds of new employees needed to meet the goals of user-fee and other programs, a paucity that could damage the agency for years to come.
You may also be interested in...
Hamburg Details Some Sequestration Impact On FDA
Commissioner says allowing the sequester would slow implementation of FDASIA provisions and reduce some overseas inspections.
Cosmetic User Fees, FDA Warnings, California: Top “Rose Sheet” Topics Of 2012
“The Rose Sheet” offers an overview of the year in cosmetics, analyzing 2012’s biggest news and the publication’s most-read stories. Highlights include a proposal in Obama’s 2013 budget request to institute cosmetics user fees, the rash of late-year warning letters and regulatory developments in California.
Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director
Nicole Verdun said children could participate in gene therapy clinical trials earlier if the necessary controls are in place.